Ask AI
AKTi or PI3Ki in MBC
Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 EBAC® CE Credit

Released: April 22, 2026

About This Tool & Disclaimer

Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer

Decera Clinical Education, LLC, is grateful to Francois-Clement Bidard, MD, PhD; Giampaolo Bianchini, MD; Nadia Harbeck, MD; Cristina Saura Manich, MD, PhD; and Peter Schmid, MD, PhD, FRCP; who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in April 2026 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal treatment choices with PI3K or AKT inhibitors in patients with hormone receptor-positive locally advanced/recurrent or metastatic breast cancer.

A series of questions allows the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include disease stage, previous therapy and duration of response to previous therapy, endocrine therapy resistance status (primary vs secondary), and the presence of actionable biomarkers including ESR1, PIK3CA, AKT, PTEN, BRCA genetic alterations and HER2 (low or ultralow expression levels).

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with locally-advanced/recurrent or metastatic breast cancer. Other considerations that are not included in the algorithm of this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate.


This tool assumes that the patient is an adult diagnosed with HR-positive breast cancer for whom systemic therapy is being considered or has started. This tool also assumes that there are no other features or specific comorbidities that would materially affect a treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline and expert recommendations for that specific patient case.

Visit the program page for additional educational content on the management of patients with HR-positive locally-advanced/recurrent or metastatic breast cancer, including a downloadable PDF resource and certified simulated case challenges authored by Giampaolo Bianchini, MD; Peter Schmid, MD, PhD, FRCP; and Giuseppe Curigliano, MD, PhD.


As a reminder, the primary focus of this treatment decision tool is identifying appropriate patients with HR-positive/HER2-negative disease who might be eligible for AKT or PI3K inhibitor therapy. For comprehensive treatment recommendations for patients with HR-positive/HER2-positive locally advanced or metastatic breast cancer and for expert insights on therapy selection including based on patient- or tumor-related characteristics, please visit the Interactive Decision Support Tool on HER2-positive breast cancer and other recently published educational resources on that topic.


This program is supported by an educational grant from F. Hoffmann-La Roche Ltd.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Francois-Clement Bidard, MD, PhD: researcher: GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, Merck Sharp & Dohme, Novartis, Personalis, Pfizer, Prolynx, Roche, Tempus; consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Foresight Dx, Inatherys, Lilly, Menarini Silicon Biosystems, Novartis, Pfizer.

Giampaolo Bianchini, MD: consultant/advisor/speaker: Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Exact Science, Gilead, Helsinn, Lilly, Menarini/Stemline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Seagen, Takeda, Tethis; researcher (paid to institution): Gilead; other financial or material support: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini/Stemline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda.

Nadia Harbeck, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Menarini/Stemline, MSD, Novartis, Pfizer, Pierre Fabre, Roche.

Cristina Saura Manich, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Phillips, Puma, Relay Therapeutics, Sanofi, Zymeworks.

Peter Schmid, MD, PhD, FRCP: consultant/advisor/speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, Roche; grant (funding to institution): Astellas, AstraZeneca, Genentech, Medivation, Merck, Novartis, OncoGenex, Roche.

©2026 Decera Clinical Education, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal treatment selection for patients with HR-positive locally advanced/recurrent or metastatic breast cancer. The information provided in the tool is based on the latest guidelines, indications, and expert guidance of Francois-Clement Bidard, MD, PhD; Giampaolo Bianchini, MD; Nadia Harbeck, MD; Cristina Saura Manich, MD, PhD; and Peter Schmid, MD, PhD, FRCP. The material published by Decera Clinical Education reflects the views of the reviewers or authors of the Decera Clinical Education material, not those of Decera Clinical Education, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in “Interactive Decision Support Tool: Expert Guidance on Selecting AKT or PI3K Inhibitors in Patients With Metastatic Breast Cancer” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education, including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2026 Decera Clinical Education, LLC. All rights reserved.

Program Content